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Prokineticin 1 Induces Inflammatory Response in
Human MyometriumA Potential Role in Initiating Term and Preterm ParturitionMarta R. Gorowiec,*† Rob D. Catalano,*
Jane E. Norman,† Fiona C. Denison,† and
Henry N. Jabbour*
From the Medical Research Council Human Reproductive
Sciences Unit * and Reproductive and Developmental
Sciences,† The Queen’s Medical Research Institute, Edinburgh,
United Kingdom
The infiltration of human myometrium and cervix
with leukocytes and the formation of a pro-inflam-
matory environment within the uterus have been
associated with the initiation of both term and pre-
term parturition. The mechanism regulating the on-
set of this pro-inflammatory cascade is not fully
elucidated. We demonstrate that prokineticin 1
(PROK1) is up-regulated in human myometrium
and placenta during labor. The expression of
PROK1 receptor remains unchanged during labor
and is abundantly expressed in the myometrium.
Gene array analysis identified 65 genes up-regu-
lated by PROK1 in human myometrium, mainly cy-
tokines and chemokines, including IL-1, chemo-
kine C-C motif ligand 3, and colony-stimulating
factor 3. In addition, we demonstrate that PROK1
increases the expression of chemokine C-C motif
ligand 20, IL-6, IL-8, prostaglandin synthase 2, and
prostaglandin E2 and F2 secretion. The treatment
of myometrial explants with 100 ng/mL of lipopoly-
saccharide up-regulates the expression of PROK1,
PROK1 receptor, and inflammatory mediators. The
infection of myometrial explants with lentiviral mi-
croRNA targeting PROK1, preceding treatment with
lipopolysaccharide, reduces the expression of in-
flammatory genes. We propose that PROK1 is a
novel inflammatory mediator that can contribute to
the onset of human parturition at term and partially
mediate premature onset of inflammatory path-
ways during bacterial infection. (Am J Pathol 2011,
179:2709–2719; DOI: 10.1016/j.ajpath.2011.08.029)Human parturition is a pro-inflammatory event associated
with the influx of leukocytes, such as neutrophils and
macrophages, to the uterus.1,2 Indeed, 40% to 60% of
genes up-regulated in the myometrium and cervix at la-
bor are involved in inflammation and chemotaxis.3 Re-
cruited leukocytes secrete cytokines, including IL-1,
IL-6, and IL-8,4 and prostaglandins E2 (PGE2) and F2
(PGF2). These cytokines and prostaglandins can stimu-
late production of matrix metalloproteinases that are in-
volved in membrane rupture5 and can also promote cer-
vical ripening.6 However, during labor, the greatest influx
of leukocytes is observed in the myometrium.1 Cytokines,
such as IL-1, released by leukocytes, promote the syn-
thesis of prostaglandin synthase 2 (PTGS2)–dependent
prostaglandins (PGE2 and PGF2), which are important
regulators of myometrial contractility.7,8 More important,
independently of prostaglandins, IL-1 also regulates
basal and store-operated calcium entry in myometrial
smooth muscle cells, which is important for contractions
of individual smooth muscle cells.9
The same pro-inflammatory events can be initiated
before 37 weeks of gestation and lead to premature onset
of parturition and preterm birth. Nearly 11% of all single-
ton deliveries are preterm, and this constitutes the big-
gest cause of neonatal morbidity and mortality.10,11 Al-
though several factors, such as smoking, alcohol,
advanced maternal age, and structural abnormalities of
the cervix,12,13 can contribute to preterm initiation of la-
bor, bacterial infection in the uteroplacental unit is be-
lieved to be a major cause. Such infections are detected
in 79% of births at 23 weeks and in 11% of births at 31 to
34 weeks.14,15 In most cases of preterm birth, even in the
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AJP December 2011, Vol. 179, No. 6absence of infection, histological evidence of inflamma-
tion is apparent in the uteroplacental unit.16,17 Intrauter-
ine inflammation is associated with adverse perinatal out-
come.18 However, therapies for preterm birth have
predominantly focused on inhibition of the onset of labor.
Therefore, there is increasing recognition that effective
therapies should target myometrial contractility and inhib-
it/reduce intrauterine inflammation.
Prokineticins 1 and 2 (PROK1 and PROK2, respectively)
are multifunctional secreted proteins that signal via two G
protein–coupled receptors termed PROK receptors 1 and 2
(PROKR1 and PROKR2, respectively). PROKs induce
smooth muscle contractility of the gut,19,20 which is medi-
ated via increased calcium influx into smooth muscle
cells.19,20 PROKs also have potent effects in multiple other
processes, including neurogenesis, angiogenesis, hemato-
poiesis, and nociception.21 There is increasing evidence
that PROK1, via PROKR1, can modulate immune re-
sponses. PROK1 can promote differentiation of bone mar-
row progenitors into macrophage-like adherent cells.22 In
addition, PROK1 induces the expression of chemokines,
including chemokine C-C motif ligand 4 (CCL4), CXCL1,
and IL-8 (CXCL8) in human monocytes, which constitutes
an important regulatory mechanism for leukocyte recruit-
ment to the site of inflammation.23
PROKs may be important regulators of female reproduc-
tive functions, including regulation of uterine receptivity24
and placental function.25–27 Considering their well-de-
scribed roles in mediating inflammatory pathways and
smooth muscle contractility, we hypothesized that PROK1,
via PROKR1, may be important in regulating events leading
to the onset of parturition. This study was designed to de-
termine the expression and potential role of PROK1 and
PROKR1 in the human myometrium during labor.
Materials and Methods
Patients and Tissue Collection
Full-thickness lower-segment biopsy specimens of hu-
man myometrium, placenta, and fetal membranes were
collected from women undergoing elective caesarean
section at term (37 weeks) before the onset of labor
(NL) and women in spontaneous labor at term (37
weeks) who required emergency lower-segment caesar-
ean section (L). Women with medical complications, such
as diabetes or hypertension, or with symptoms of infec-
tion (determined by temperature 38°C) were excluded
from the study. Patients were also excluded if the preg-
nancy was multiple or if they received either prostaglan-
din for induction or oxytocin for augmentation of labor.
Written consent was obtained from each patient before
recruitment, in accordance with approval from the Loth-
ian Local Research Ethics Committee (REC reference no.
07/S1103/25). Immediately after collection, tissue was
placed in RNAlater (Applied Biosystems, Warrington, UK)
for RNA extraction, fixed in 4% neutral-buffered formalin,
and wax embedded for immunohistochemistry (IHC).Tissue Culture and Treatments
Myometrial tissue explants from women at term and not in
labor were collected for in vitro studies. Tissue was rou-
tinely maintained in RPMI 1640 medium (GIBCO, Invitro-
gen, Paisley, UK) supplemented with 100 IU penicillin
and 100 g/mL streptomycin (Sigma, Poole, UK) at 37°C
and 5% CO2, as recommended. After collection, explants
were finely chopped into equal portions with scissors and
incubated overnight. Tissue was treated with vehicle
(sterile double-distilled water), 100 ng/mL of lipopolysac-
charide (LPS) from Salmonella abortus equi (Alexis Bio-
chemicals, Axxora, Nottingham, UK), or 40 nmol/L
PROK1 (PeproTech, London, UK) for 2, 4, 6, 8, and 24
hours. In previous studies, the PROK1 and LPS doses
used in this study have given optimal responses.28,29
Tissue and supernatants were collected at all time points.
All experiments were performed in duplicate.
Gene Array and Data Analysis
Total RNA was extracted from myometrial explants
treated with either vehicle or 40 nmol/L PROK1 for 6 and
24 hours (n  6 for each time point). Sample preparation,
array hybridization, and data analysis were performed by
the Finnish Microarray and Sequencing Centre and the
Turku Centre for Biotechnology (Turku, Finland). Briefly,
total RNA was biotin labeled by a single in vitro transcrip-
tion amplification step. Samples were hybridized to Illu-
mina Human HT-12 v.3 Expression BeadChips (Illumina,
San Diego, CA) and stained with streptavadin-Cy3. Sig-
nal intensities within data sets were normalized by apply-
ing quantile normalization. R package Limma30 (Biocon-
ductor, Open Source Software for Bioinformatics) was
used for performing the statistical testing between the
groups. Functional grouping of the gene list into statisti-
cally significant overrepresented ontologies was per-
formed using the protein analysis through evolutionary
relationships database analysis tools (PANTHER).31
TaqMan Quantitative Real-Time PCR
Tissue was homogenized in QIAzol (Qiagen, Crawley, UK),
followed by RNA extraction with on-column DNase digestion
using the RNeasy Mini Kit, according to the manufacturer’s
instructions (Qiagen). RNA was reverse transcribed using the
VILO SuperScript VILO cDNA Synthesis Kit (Invitrogen). Taq-
Man quantitative real-time PCR was performed using an ABI
Prism 7500 System (Applied Biosystems). The sequences of
all primers and FAM-labeled probes are listed in Table 1. The
expression of target genes was normalized to RNA loading,
measured with primers and VIC-labeled probe for ribosomal
18S RNA. Relative gene expression was calculated by using
the comparative CTmethod. Results of in vitro experiments are
presented relative to expression in vehicle-treated samples. A
comparison of gene expression in tissues collected from
women in labor versus not in labor is presented as relative to a
calibrator endometrial sample included in all reactions.28
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Paraffin-embedded sections were dewaxed in xylene
and dehydrated in graded ethanol. Antigen retrieval was
performed by boiling for 5 minutes in 0.01 mol/L citrate
buffer (pH 6.0), followed by quenching the activity of
endogenous peroxidase with 30% H2O2 in methanol.
Table 1. Sequences of Primers and Probes Used for Analysis of
Gene Expression by TaqMan Quantitative Real-Time
PCR
Gene Sequence or category number
PROK1
Forward 5=-GTGCCACCCGGGCAG-3=
Reverse 5=-AGCAAGGACAGGTGTGGTGC-3=
FAM 5=-ACAAGGTCCCCTTGTTCAGGAAACGCA-3=
CCL20
Forward 5=-TCCTGGCTGCTTTGATGTCA-3=
Reverse 5=-CCAAGACAGCAGTCAAAGTTGCT-3=
FAM 5=-TGCTGCTACTCCACCTCTGCGGC-3=
PROKR1
Forward 5=-TCTTACAATGGCGGTAAGTCCA-3=
Reverse 5=-CTCTTCGGTGGCAGGCAT-3=
FAM 5=-TGCAGACCTGGACCTCAAGACAATTGG-3=
IL-1
Forward 5=-CGCATCCAGCTACGAAT-3=
Reverse 5=-CATGGCACAACAACTGA-3=
FAM 5=-CGACCACCACTACAGC-3=
IL-6
Forward 5=-GCCGCCCCACACAGACA-3=
Reverse 5=-CCGTCGAGGATGTACGGAAT-3=
FAM 5=-
CCACTCACCTCTTCAGAACGAATTGACAAAC-3=
IL-8
Forward 5=-CTGGCCGTGGCTCTCTT-3=
Reverse 5=-TTAGCACTCCTTGGCAAAACTG-3=
FAM 5=-CCTTCCTGATTTCTGCAGCTCTGTGTGAA-
3=
COX-2
Forward 5=-CCTTCCTCCTGTGCCTGATG-3=
Reverse 5=-ACAATCTCATTTGAATCAGGAAGCT-3=
FAM 5=-TGCCCGACTCCCTTGGGTGTCA-3=
18S
Forward 5=-CGGCTACCACATCCAAGGAA-3=
Reverse 5=-GCTGGAATTACCGCGGCT-3=
VIC 5=-TGCTGGCACCAGACTTGCCCTC-3=
CCL3 Hs00234142-m1
CSF3 Hs99999083-m1
VCAM1 Hs01003372-m1
TACC2 Hs00610617-m1
CCL2 Hs00234140-m1
CCL8 Hs00271615-m1Sections were blocked in a solution of 20% normal goat
serum and 5% bovine serum albumin at room tempera-
ture, followed by incubation with rabbit anti-human
PROK1 at 1:500 dilution (Phoenix Pharmaceuticals, Bel-
mont, CA) or PROKR1 at 1:250 dilution (Life Span Biosci-
ences, Atlanta, GA) overnight at 4°C; negative controls
were incubated with rabbit IgG (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA). Subsequently, sections were incu-
bated with biotinylated goat anti-rabbit antibody (Vector
Laboratories, Peterborough, UK) (1:500), followed by in-
cubation with streptavidin–horseradish peroxidase (GE
Healthcare UK, Little Chalfont) (1:1000). Staining was
detected with 3,3=-diaminobenzidine (Vector Laborato-
ries, Peterborough, UK) as the chromogen.
Lentivirus miRNA Gene Silencing
Lentivirus microRNA (miRNA) targeting PROK1 mRNA
was used to knock down PROK1 expression, as previ-
ously described.28,32 Briefly, myometrial explants (n  8)
were finely chopped and subsequently infected with len-
tivirus containing scrambled sequence (plenti6/V5-
EmGFP-miR-neg) as a negative control or PROK1 miRNA
(pLenti6/V5-EmGFP-hum-PROK1-72-287) chained con-
structs for 72 hours. Subsequently, explants were incu-
bated in the presence or absence of 100 ng/mL of LPS for
24 hours. Tissue and supernatants were then harvested,
and RNA was extracted from tissues for PCR analysis.
Results are presented relative to expression in vehicle-
treated samples.
Measurement of Prostaglandins PGE2
and PGF2
Myometrium explants (n  5) were incubated in the pres-
ence or absence of 40 nmol/L PROK1 for 24 hours. Me-
dium was collected and assayed by enzyme-linked im-
munosorbent assay for PGE2 and PGF2, as previously
described.33 Results are presented as pg/mg tissue.
Measurement of IL-1, CCL3, and CCL20
Myometrial explants were infected with lentiviral con-
structs containing scrambled or PROK1 miRNA and sub-
sequently treated with 100 ng/mL of LPS for 24 hours, as
previously described. Conditioned media were collected
Figure 1. Expression of PROK1 and PROKR1
mRNA in human uteroplacental tissues at term.
PROK1 mRNA expression is elevated in myome-
trium and placenta during labor at term com-
pared with the tissues collected at term before
the onset of labor (A). Levels of PROKR1 mRNA
do not vary with the onset of labor; however,
notably, PROKR1 levels are highest in myome-
trium compared with other uteroplacental tis-
sues (B). Results are presented as mean  SEM.
*P  0.05, **P  0.0001 (n  10 to 12).
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propriate DuoSet ELISA Development Systems, accord-
ing to the manufacturer’s protocols (R&D Systems,
Abingdon, UK). Briefly, 96-well microplates were coated
overnight with 100 L of working concentration of appro-
priate Capture Antibody diluted in PBS (1:180). The fol-
lowing day, the plates were blocked with 300 L of 1%
bovine serum albumin in PBS for 1 hour at room temper-
ature. Subsequently, 100 L of samples and appropriate
standards were added for 2 hours, followed by incuba-
tion with Detection Antibody diluted (1:180) for 2 hours
and then incubation with streptavidin–horseradish perox-
idase (1:200) for 20 minutes. After the addition of TMB
Substrate Solution, optical density was determined at 450
nm using a microplate reader. Results are presented
relative to expression in vehicle-treated samples.
Figure 3. Validation of gene array analysis by quantitative real-time PCR. A:
and low-intensity signals and genes that were up- or down-regulated at ei
myometrial explants with PROK1 for 24 hours up-regulates expression of
containing protein 2 remained unaffected. C: Treatment of myometrial explants with 4
there was no difference in the expression of CCL2. *P  0.05, **P  0.005, and ***P Statistical Analysis
Data were analyzed using an unpaired t-test with Welch’s
correction or a paired t-test (GraphPad Prism 5.0; Graph-
Pad Software, La Jolla, CA). The n values represent the
number of independent experiments. Unless otherwise
indicated, data are given as mean  SEM.
Results
Expression of PROK1 Increases in
Uteroplacental Tissues at Labor
PROK1 mRNA expression is significantly elevated during
labor (L) versus not labor (NL) in the myometrium (16.78 
Figure 2. Immunolocalization of PROK1 and
PROKR1 in myometrium collected from women
at term before the onset of labor or during labor.
PROK1 is localized to the smooth muscle bun-
dles (A, not in labor; B, in labor). PROKR1 was
also immunolocalized to the smooth muscle
bundles in myometrial tissue collected from
women not in labor (C) and in labor (D). During
labor, PROKR1 expression is also localized to
vasculature. Control sections were negative for
immunoreactivity (insets). E, endothelium;
SMB, smooth muscle bundles (n 16: n 8 for
myometrium collected from women not in la-
bor, and n  8 for myometrium collected from
women in labor).
enes selected to verify the array analysis, including genes representing high-
6- or 24-hour time point. Adj, adjusted; FC, fold change. B: Treatment of
CL3, CSF3, and VCAM1, whereas levels of transforming acidic coiled-coil–List of g
ther the
IL-1, C0 nmol/L PROK1 for 6 hours elevated expression of CCL3 and CCL8, whereas
0.0001. n/s, not significant (n  6). Results are presented as mean  SEM.
The cutoff was established by quantitative PCR verification, a fold
change 1.5, and an adjusted P value 0.1.
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(1.97  0.56-fold versus 0.9  0.17-fold; P  0.05) but
not in fetal membranes (Figure 1A). PROKR1 expression
does not change at term with the onset of labor in any of
the uteroplacental tissues. However, expression is high-
est in the myometrium compared with other uteroplacen-
tal tissues (P  0.0001), suggesting that myometrium
may be the main target tissue for PROK1 signaling during
labor (Figure 1B).
We subsequently focused on the role of PROK1 and
PROKR1 in human myometrium. During IHC, PROK1 was
localized in the smooth muscle bundles in the myome-
trium of women at term before the onset of labor (Figure
2A) and during labor (Figure 2B). Similarly, PROKR1 was
immunolocalized to the smooth muscle bundles in myo-
metrial tissue collected from women at term before the
onset of labor (Figure 2C) and during labor (Figure 2D).
During labor, PROKR1 expression is additionally local-
ized to the vasculature (Figure 2D).
PROK1/PROKR1 Regulates Inflammatory
Mediators in Human Myometrium
After having established that PROK1 expression is ele-
vated in the myometrium during labor and that PROKR1
transcript levels are highest in myometrial tissue, we
sought to identify the downstream targets of PROK1/
PROKR1 signaling in the myometrium. Gene array anal-
ysis was used to identify PROK1-regulated transcripts in
myometrial explants at term (in six independent sam-
ples), treated with 40 nmol/L PROK1 for 6 or 24 hours
and compared with vehicle treatment for each time point.
The array analysis identified both up- and down-regu-
lated transcripts at both time points (see Supplemental
Figure S1, A and B, at http://ajp.amjpathol.org; http://
www.ncbi.nlm.nih.gov/geo, Accession no. GSE28272),
with an increase in the number of regulated transcripts
from 6 to 24 hours (see Supplemental Figure S1C at
http://ajp.amjpathol.org). The analysis shown there was a
distinct response at 6 hours after PROK1 treatment com-
pared with the response at 24 hours, although approxi-
mately 30% of the genes at 6 hours were common to
24-hour treatment, indicating a sustained regulation of a
subset of genes. Genes were selected to verify the array
analysis by real-time PCR. These genes were selected to
represent high- and low-intensity signals and genes that
were up- or down-regulated at either time point (Figure
3A). PCR verification confirmed the increased expression
of CCL3 and CCL8 at 6 hours (Figure 3C) and IL-1,
CCL3, colony-stimulating factor 3 (CSF3), and vascular
cell adhesion molecule 1 (VCAM1) at the 24-hour time
point (Figure 3B). However, PCR did not validate regula-
tion of transforming acidic coiled-coil–containing protein
2 and CCL2. The PCR validation permitted cutoff values
to be established to generate a reliable list of 65 PROK1
regulated genes (Table 2). The gene list indicated that
the response to PROK1 at 6 hours was mainly constituted
of chemokine genes (7 of the 11 genes). Also, chemo-
kines (ie, CCL3, CCL3L1, and CCL3L3) represented the
genes that were regulated at both 6 and 24 hours afterTable 2. Differential Gene Expression of 65 Genes after PROK1
Treatment of Term Myometrial Explants
Gene
Mean fold
change
Adjusted
P value Time (hours)
ADAMDEC1 1.6 0.0741 24
AMPD3 1.6 0.0861 24
BDKRB1 1.9 0.0506 24
C15orf48 3.2 0.0327 24
C8orf4 1.6 0.0506 24
CCL20 3.9 0.0709 24
CCL3 5.5 0.0001 6
CCL3 2.6 0.0296 24
CCL3L1 3.6 0.0017 6
CCL3L1 2.5 0.0327 24
CCL3L3 4.9 0.0011 6
CCL3L3 3.2 0.0249 24
CCL4L1 2.6 0.0118 6
CCL4L2 6.9 0.0000 6
CCL8 3.6 0.0071 6
CCR7 2.0 0.0969 24
CD82 1.8 0.0420 24
CSF3 4.5 0.0249 24
CX3CL1 3.0 0.0100 6
CXCL1 2.6 0.0249 24
CXCL2 3.1 0.0474 24
CXCL5 5.0 0.0000 24
CXCL6 5.3 0.0062 24
CYP27B1 3.0 0.0709 24
ELL2 1.6 0.0085 24
FBP1 1.8 0.0709 24
FCGR2A 1.6 0.0900 24
G0S2 1.9 0.0841 24
HCK 1.8 0.0792 6
IL1B 5.3 0.0249 24
IL1RN 2.3 0.0861 24
IL24 3.2 0.0581 24
IL32 1.7 0.0280 24
IL7R 2.5 0.0177 24
IRAK2 1.8 0.0474 24
LILRB4 1.6 0.0177 24
LTB 2.7 0.0249 24
MEOX1 2.6 0.0018 6
MME 1.6 0.0769 24
MMP9 3.5 0.0313 24
MT1H 2.1 0.0275 24
MUCL1 2.0 0.0799 24
NAMPT 1.7 0.0249 24
NFKB2 1.5 0.0747 24
NFKBIZ 1.9 0.0707 24
NRCAM 1.5 0.0615 24
OLR1 1.9 0.0387 24
OSM 1.9 0.0474 24
PDE4B 1.8 0.0327 24
PPL 1.6 0.0709 24
PSME2 1.5 0.0480 24
RCSD1 1.5 0.0383 24
RND1 1.9 0.0172 6
SELE 6.0 0.0496 6
SEMA4A 1.7 0.0085 24
SERPINB2 4.0 0.0085 24
SERPINB7 3.5 0.0870 24
SLC11A2 1.5 0.0730 24
SLC39A14 1.6 0.0280 24
SOCS1 1.5 0.0348 24
SRGN 1.7 0.0724 24
TNFAIP8 1.6 0.0861 24
TNFRSF6B 1.7 0.0056 24
TNIP1 1.6 0.0249 24
UBD 2.3 0.0709 24
VCAM1 3.2 0.0474 24
WNT5A 1.6 0.0841 24
ZC3H12A 1.8 0.0673 24
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ter 24 hours consisted mainly of chemokines and cyto-
kines (ie, 22 of the 57 genes). A functional grouping of the
gene list into statistically significant overrepresented on-
tologies revealed the immune response and related path-
ways to predominate, including macrophage activation
and response to interferon- (Table 3).
Selected PROK1 up-regulated genes identified from
the gene array list were analyzed for expression in term
myometrium in L versus NL. The analysis demonstrated
that the following cytokines are up-regulated during la-
bor: IL-1 (L versus NL, 16.78  7.0-fold versus 1.16 
0.37-fold; P  0.05), CCL3 (L versus NL, 12.79  5.23-
fold versus 1.3  0.33-fold; P  0.05), and CSF3 (L
versus NL, 66.7  57.28-fold versus 0.06  0.33-fold;
P  0.0001). There was no change in expression of
VCAM1 (L versus NL, 10.36  2.4-fold versus 13.04 
4.91-fold) or CCL8 (NL versus L, 13.45  4.9-fold versus
27.82 12.02-fold) (Figure 4). An elevation in expression of
PROK1 at labor is included in the figure for comparison.
There were several genes demonstrated by the gene
array to be up-regulated in response to PROK1, such as
PTGS2, IL-6, IL-8, and CCL20; however, they were less
than cutoff values. Nevertheless, because they play an
important role in the physiological characteristics of labor
and have been previously demonstrated to be up-regu-
lated in the myometrium during labor,3 we sought to
confirm whether they are regulated by PROK1. We dem-
onstrate that treatment with PROK1 resulted in up-regu-
lation of mRNA levels for the following variables: PTGS2
(3.89  1.38-fold over vehicle, P  0.05), IL-6 (3.2 
0.76-fold over vehicle, P 0.05), IL-8 (4.6 1.4-fold over
vehicle, P  0.05), and CCL20 (6.27  2.39-fold over
Table 3. Over-represented PANTHER Ontologies
Biological process
No. o
in the
Immune response
Immune system process 2
Response to stimulus 1
Cell-cell signaling 1
Cell surface receptor–linked signal transduction 2
Signal transduction 4
Cell communication 4
Macrophage activation
Cellular process 6
Cellular defense response
Intracellular signaling cascade 1
Response to interferon-
Angiogenesis
B-cell–mediated immunity
Mesoderm development 1
Response to external stimulus
Blood coagulation
Natural killer cell activation
Cell motion
Apoptosis
Cell-cell adhesion
System development 2
Cell adhesion 1
PANTHER, protein analysis through evolutionary relationships.vehicle, P  0.05) (Figure 5A). We also demonstrate thatthe increase in PTGS2 transcript levels is reflected by an
increase in the secretion of PTGS2-dependent prosta-
glandins: PGE2 (Figure 5B) [70.7  17.1 versus 12.14 
2.28 pg/mL/mg tissue for PROK1 versus vehicle treat-
ment; P  0.05] and PGF2 (Figure 5C) (32.54  10.9
versus 11.84  4.22 pg/mL/mg tissue for PROK1 versus
vehicle treatment; P  0.05).
LPS Increases Expression of PROK1 and
PROKR1 in Term Myometrium
Subsequently, we examined whether treatment with a
mimetic of infection, such as LPS, can regulate the ex-
pression of PROK1 and PROKR1. Treatment of term myo-
metrial explants with 100 ng/mL LPS resulted in an in-
crease in PROK1 mRNA at 2 hours (58.29  30.25-fold
Figure 4. PROK1-regulated genes are elevated in myometrium during labor.
The expression of genes that were demonstrated by gene array to be up-
regulated in response to PROK1 was subsequently examined in term myo-
metrium NL versus term myometrium L. Quantitative real-time PCR analysis
demonstrated that IL-1, CCL3, and CSF3 are up-regulated at labor, similar to
s
ry
No. of genes
in the
PROK1 list
No. of genes
expected P value
23 2.39 4.54  10-17
36 8.32 2.63  10-16
29 5.69 1.78  10-14
25 4.21 8.34  10-14
30 7.07 6.25  10-13
39 13.26 2.58  10-12
39 13.81 9.76  10-12
10 0.97 4.33  10-8
40 19.80 1.67  10-7
10 1.45 1.71  10-6
16 4.96 2.21  10-5
5 0.33 2.22  10-5
8 1.29 4.41  10-5
7 0.99 6.19  10-5
14 4.83 2.50  10-4
6 1.03 5.80  10-4
6 1.03 5.80  10-4
4 0.38 6.10  10-4
10 3.05 8.55  10-4
9 3.06 3.27  10-3
8 2.53 3.63  10-3
14 6.43 3.93  10-3
10 4.22 8.77  10-3f gene
catego
756
628
798
331
235
191
365
305
258
457
568
105
408
314
528
325
325
121
964
966
799
031
333PROK1, whereas there was no change in the level of VCAM1 and CCL8. *P 
0.05, **P  0.0001 (n  10). Results are presented as mean  SEM.
IL-8, an
(n  5).
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(3.84  1.6-fold over vehicle; P  0.05) (Figure 6).
PROK1 Mediates LPS-Induced Inflammation in
Term Myometrium
Several inflammatory mediators that are elevated during
labor are also induced by bacterial infection.34,35 After
having demonstrated up-regulation of PROK1 and
PROKR1 in response to LPS and PROK1-mediated reg-
ulation of inflammatory factors, we aimed to determine
whether the pro-inflammatory effect of LPS is mediated
via PROK1. Myometrial tissue was infected with lentiviral
constructs containing a scrambled control miRNA se-
quence or a PROK1 chained miRNA sequence and sub-
sequently treated with vehicle or 100 ng/mL of LPS. The
expression of PROK1 was efficiently suppressed in myo-
metrial tissue in response to infection with PROK1 miRNA
versus scrambled miRNA (0.22  0.07-fold versus 1.2 
0.39-fold; P  0.05) (see Supplemental Figure S2 at
http://ajp.amjpathol.org). The infection of myometrial tis-
sue with PROK1 miRNA decreased the response to LPS:
IL-1 (57.21  17.87-fold after infection with scrambled
miRNA versus 9.53  4.23-fold after infection with
PROK1 miRNA), CCL3 (16.6  3.65-fold after infection
with scrambled miRNA verus 5.9 2.7-fold after infection
with PROK1 miRNA), CSF3 (25.52  18.81-fold after in-
fection with scrambled miRNA versus 1.68  0.53-fold
after infection with PROK1 miRNA), and CCL20 (50.1 
3.65-fold after infection with scrambled miRNA versus
5.9  2.4-fold after infection with PROK1 miRNA) (P 
Figure 5. PROK1 up-regulates the expression of inflammatory mediators in
with 40 nmol/L PROK1 for 24 hours increased mRNA levels for PTGS2, IL-6,
of PTGS2-dependent prostaglandins, PGE2 (B) and PGF2 (C), at 24 hours0.05 for all genes) (Figure 7, A–D). However, there was no
effect of PROK1 suppression on the level of PTGS2
(2.9  0.74-fold after infection with scrambled miRNA
versus 3.3 1.84-fold after infection with PROK1 miRNA)
(Figure 7E). As a negative control, we demonstrated that
there was no effect of LPS on PTGS1 expression or when
PROK1 was suppressed (Figure 7F). These data suggest
that LPS-induced inflammation in term myometrium may
be partially mediated via expression of PROK1.
We subsequently investigated the effect of PROK1
suppression on secreted proteins in the supernatants of
myometrial explant cultures. The treatment of myometrial
explants with PROK1 miRNA reduced secretion of IL-
(13.92  3.86-fold after infection with scrambled miRNA
versus 0.58  0.17-fold after infection with PROK1
miRNA), CCL3 (69.6  26.23-fold after infection with
scrambled miRNA versus 5.34  1.76-fold after infection
with PROK1 miRNA), and CCL20 (39.5  22.25-fold after
infection with scrambled miRNA versus 1.63  0.97-fold
after infection with PROK1 miRNA (P  0.05 for all pro-
teins) (Figure 8, A–C).
Discussion
Human parturition is well described as a pro-inflamma-
tory event associated with recruitment of leukocytes,
mainly neutrophils and macrophages, to the myometrium
and cervix.1 Data indicate that 40% to 60% of genes
up-regulated in these tissues at labor are involved in
inflammation and chemotaxis.3 Recruited leukocytes se-
crete cytokines, such as IL-1, IL-6, and IL-8, and pros-
in term and preterm onset of parturition. Treatment of myometrial explants
d CCL20 (n  8) (A). Treatment with 40 nmol/L PROK1 promoted secretion
*P  0.05. Results are presented as mean  SEM.
Figure 6. LPS promotes expression of PROK1
and PROKR1 in term myometrium. Myometrial
explants collected from women at term, not in
labor, were treated with 100 ng/mL LPS for 24
hours. Treatment with LPS up-regulated the
mRNA level for PROK1 (A) and PROKR1 (B).
*P  0.05 (n  8). Results are presented as
mean  SEM.volved
PTGS2
significa
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ulate production of matrix metalloproteinases that are
involved in membrane rupture5 and can also promote
cervical ripening.4 Although inflammatory events during
parturition are well characterized, the underlying mecha-
nism remains unknown.
Increasing evidence suggests that PROK1 can mod-
ulate immune responses. The expression of PROK1
and PROKR1 is increased at sites where inflammation
occurs, and they are involved in mediating inflamma-
tory pain.36,37 PROK1 promoted differentiation of bone
marrow progenitors into macrophage-like adherent
cells in a mouse model and in human progenitor
cells.22 PROK1 also induces expression of CCL4,
CXCL1, and IL-8 in human monocytes, which is a part
of an important regulatory mechanism for leukocyte
recruitment to the site of inflammation.23 We have pre-
viously demonstrated that the expression of PROK1
and PROKR1 plays an important role during preg-
Figure 7. PROK1 mediates LPS-induced expression of inflammatory mediato
constructs targeting PROK1 or scrambled sequence. Infected explants were s
CCL3 (B), CSF3 (C), and CCL20 (D) in response to 100 ng/mL of LPS was
sequence. However, PROK1 suppression did not reduce the effect of LPS on
remained unaffected when PROK1 was suppressed (F). *P  0.05. n/s, not
Figure 8. Targeting the PROK1 gene with miRNA reduces the secretion o
lentivirus containing miRNA constructs targeting PROK1 or a scrambled sequ
of LPS for 24 hours. Results are presented relative to expression in vehic
supernatants after treatment with LPS were reduced in tissues infected with PROK1 m
(n  5 to 7). Results are presented as mean  SEM.nancy.24 However, the expression of PROK1 and
PROKR1 is also elevated during the third trimester in
the placenta, where it regulates the expression of in-
flammatory mediators with established roles in the ini-
tiation of labor: IL-8 and PTGS2.25 This finding sug-
gests that PROK1 may contribute to the induction of
processes leading to the onset of parturition.
We demonstrate that the expression of PROK1 is
significantly increased in term myometrium and pla-
centa at labor compared with nonlaboring tissues.
However, although not significantly affected by labor,
the expression of PROKR1 is abundantly expressed in
myometrium, suggesting that, within the uteroplacental
unit, the myometrium is a major target tissue for PROK1
action.
Immunolocalization of PROKR1 demonstrated ex-
pression in term myometrium, predominantly in smooth
muscle cells, confirming what we previously observed
in nonpregnant myometrium.38 Because PROK1 was a
ometrium. Term myometrium was infected with lentivirus containing miRNA
ntly treated with 100 ng/mL of LPS for 24 hours. The expression of IL-1 (A),
ntly decreased by PROK1 miRNA constructs compared with the scrambled
expression (E). LPS treatment had no effect on PTGS1 expression, and this
nt (n  8). Results are presented as mean  SEM.
matory proteins in response to LPS. Term myometrium was infected with
fected explants were subsequently treated with either vehicle or 100 ng/mL
d samples. IL-1 (A), CCL3 (B), and CCL20 (C) protein levels in culturers in my
ubseque
significaf inflam
ence. In
le-treateiRNA compared with tissues infected with a scrambled sequence. *P  0.05
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results indicate that elevated expression of PROK1 in
the myometrium, with the onset of labor, may regulate
contractions of smooth muscle cells, resulting in uter-
ine contractions during labor. This is further supported
by the regulatory effect of PROK1 on expression of
IL-1 demonstrated in this study. IL-1 plays a pivotal
role in uterine contractility because it promotes an in-
flux of calcium into uterine smooth muscle cells, en-
hancing contraction.9 In addition, IL-1, via induction
of PTGS2, stimulates production of prostaglandins that
are well described to induce contractions of the
uterus.7,8 More important, our results demonstrate that
PROK1 up-regulates expression of PTGS2 and secre-
tion of PGE2 and PGF2. It is possible that this occurs
directly via PROK1 regulation of PTGS2 expression24
and/or indirectly via prior induction of IL-1. These
data warrant further research to confirm a role of
PROK1/PROKR1 in myometrial contractility.
By using microarray gene expression analysis, we ex-
amined the effect of PROK1 on gene expression in myo-
metrial tissue before the onset of labor at term. We iden-
tified 65 genes to be regulated by PROK1 in the
myometrium, most of which are cytokines and chemo-
kines. A functional grouping of these genes revealed that
immune response and related pathways are predomi-
nantly regulated by PROK1, including IL-1, CCL3,
CSF3, CCL20, IL-6, IL-8, and PTGS2, which have been
previously up-regulated in human myometrium and cer-
vix during labor.3 Such a pronounced effect of PROK1 on
immune pathways suggests that PROK1 may regulate
recruitment of leukocytes to the myometrium at term and
their activation and, thus, contributes to the initiation of
parturition.
IL-1, IL-8, and IL-6 may constitute an initial pro-in-
flammatory stimulus that then further establishes an in-
flammatory microenvironment in the uterus by activating
local cells to secrete chemoattractants or effector mole-
cules, such as prostaglandins or matrix metalloprotei-
nases.39,40 IL-8, which in gestational tissues is mainly
stimulated by IL-1, is a potent chemoattractant and ac-
tivating factor, mainly for neutrophils.41,42 Its concentra-
tions correlate with the number of neutrophils and mac-
rophages in the lower segment of the myometrium and
cervix.2,43 The main role of IL-8 during parturition may be
to maintain neutrophil numbers in gestational tissues and
disseminate a pro-inflammatory state.40 As labor pro-
gresses, the initial neutrophil influx may be followed by
monocyte recruitment, which is believed to be regulated
by IL-6.3,44 Monocytes further promote inflammation by
producing chemokines, such as CCL2, CCL3, CCL8, or
CCL20, that are involved in further recruitment of leuko-
cytes.40
During parturition, the absolute and percentage num-
bers of circulating neutrophils and monocytes are in-
creased, indicating that proliferation of these cells is en-
hanced during labor.45 Our results suggest that PROK1
may also regulate this process. In addition to regulation
of IL-8 and IL-6, we demonstrate that PROK1 up-regu-
lates the expression of CSF3. The main function of CSF3
is to stimulate bone marrow to produce and mobilizeneutrophils to the bloodstream and initiate their differen-
tiation.46,47 This is vital for the physiological features of
labor, which is well associated with an influx of neutro-
phils to the myometrium and cervix.
In preterm birth, the pro-inflammatory environment is
initiated prematurely. Although several factors, such as
smoking, alcohol, advanced maternal age, and struc-
tural abnormalities of the cervix,12,13 can contribute to
preterm initiation of labor; bacterial infections account
for nearly 25% of all incidents of preterm deliveries and
they are detected in 79% of births at 23 weeks and in
11% of births at 31 to 34 weeks.14,15 More important,
antimicrobial therapies with antibiotics have had little
or no benefit.15 In most cases, even though intrauterine
infections are polymicrobial, Escherichia coli and LPS
demonstrate the most robust effect on concentration of
prostaglandins PGE2 and PGF2 and cytokines, such
as IL-1, IL-6, and IL-8.48 In most cases, evidence of
intrauterine infection is not apparent or underlying in-
fection is asymptomatic; nevertheless, histological ev-
idence of inflammation is present in the decidua, fetal
membranes, and umbilical cord.16,17,49,50 Therefore,
targeting downstream inflammation could constitute a
novel and beneficial solution to prevent bacterially in-
duced preterm births.
In this study, we demonstrate that several genes reg-
ulated by PROK1 increase during parturition both term
and preterm and are associated with intrauterine bacte-
rial infection.34,35,51 Considering the induction of PROK1
and PROKR1 by LPS, we suggest that the role of PROK1
in inducing a pro-inflammatory response may contribute
to the activation of inflammatory events and preterm birth
associated with bacterial infections.
Further evidence to support a role of PROK1 in medi-
ating an inflammatory response was shown using a mi-
metic of infection, LPS. We selected three genes that
were demonstrated by the gene array to be the most
responsive to PROK1 (IL-1, CCL3, and CFS) and also
included CCL20 and PTGS2. The study demonstrated
that LPS induction of pro-inflammatory genes CCL20,
CCL3, CFS, and IL-1 is decreased by inhibiting PROK1
gene expression. LPS may regulate the expression of
these genes in the human myometrium via toll-like recep-
tor 2, which is similar to PROK1 and localizes to smooth
muscle bundles.52
Our study demonstrates a novel role for PROK1 in
regulating a wide range of inflammatory mediators in
human myometrial tissue, which plays a pivotal role in the
physiological characteristics of labor. We propose that
PROK1 regulates inflammatory processes, in particular
those involved in the recruitment of leukocytes to the
myometrium, which, in turn, contribute to the onset of
parturition at term. In addition, PROK1 may meditate the
inflammatory cascade in myometrium during infection,
resulting in premature initiation of labor. Therefore, tar-
geting PROK1 signaling could provide novel and efficient
therapy by reducing the inflammatory response during
premature initiation of labor and, hence, improve neona-
tal survival.
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